Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis.
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Esther W Chan The prevalence of different strains of C. difficile varies substantially by region. Ribotyping has shown that the most frequent ribotypes in Australia are 014 and 002, [6] in China it is 017, 046, and 012; in Japan 018, 014, 002, 001, Korea 018, 017, Taiwan 017, and Hong Kong it is 002. [7] This compares with Europe where the ribotypes are 027, 014,001/072, and 078. [8] This may have implications for the risk of C. difficile infections from proton pump inhibitors.
In some C. difficile ribotypes the level of expression of toxin genes and their regulators was greater at higher pH levels and elevated even further in the presence of PPIs. [9] For ribotype 001, PPI exposure was associated with a 120-fold higher expression of tcdA at higher pH levels, while for ribotypes 027 and 028, more than 50 fold increases were observed at higher pH levels. For tcdB and cdtB expression the relationship was less clear. [9] Whether the differing prevalence of different strains of C. difficile and the potential for PPIs to affect toxin gene expression differently according to strain means that differences in risk of PPI induced C. difficile can be observed across countries is unclear. This research aimed to establish the risk of C. difficile infections associated with initiation of PPIs in countries in the Asia-Pacific region. We undertook a multi-country study, which included 4 countries (6 databases) from the Asia Pacific region. We also included data from Canada which provided a contemporary reference point, as much of the previous research had been undertaken in North America or Europe.
[1] We used sequence symmetry analysis, [10] which has the advantage of inherently controlling for measured and unmeasured confounders that are stable over time. All prior research has used cohort or case-control study designs which may have residual confounding due to unmeasured confounders. We had national data for four of the countries involved, thus providing the largest study sample to date to assess the association between proton pump inhibitor use and C. difficile infection.
Methods

Data sources
This multi country study was initiated by Health Canada, with participation from the member groups of the Asian PharmacoEpidemiology Network (AsPEN).
[11] AsPEN provides a mechanism to support the conduct of cross-country pharmacoepidemiological research to facilitate prompt detection and communication of emerging safety issues between countries.
The data sources used are listed in table 1, with full details of the databases published elsewhere. [12] All datasets held patient level dispensing data which included: a patient identifier, patient demographics, date of medicine supply, medicine dispensed, quantity and strength. Medicines were mapped from individual country specific codes to the WHO Anatomical Therapeutic Chemical (ATC) classification codes.
[13]
Study design
We used sequence symmetry analysis,[10] that compares the sequence by which people initiate the same two medicines within a defined period of time.
[10] The method has been validated as an adverse event signal detection tool against adverse events identified in randomised controlled trials and against negative controls from product information of unrelated products, as well as in a simulation study. [14] [15] It's performance has been shown to be similar to disproportionality methods. [14] We assessed the association between proton pump inhibitor use and C. difficile using oral vancomycin as the marker medicine for C. difficile. Oral vancomycin use would be expected to rise after PPI initiation if there was an association with C. difficile infection as oral vancomycin is only indicated for C. difficile infections and staphylococcal enterocolitis. [16] Oral vancomycin has been used as a marker of C. difficile infections in previous research. [17] Vancomycin's poor absorption from the gastrointestinal tract makes it unsuitable for other types of infection, so risk of misclassification bias was low.
A distributive network model [18] was employed. The co-ordinating centre for this study, the helicobacter eradication therapy co-pack were excluded. We included a sensitivity analysis, where metronidazole was used as the indicator medicine. Metronidazole is used first line in many settings for treatment of C.difficile infections, however, it is also used for conditions other than C.difficile infection, so is not as specific an indicator.
In the SSA method, the date of incident dispensing of proton pump inhibitors and oral vancomycin was determined for each individual patient. All incident dispensings that occurred within one year of each other for the same person were included in the analysis. We excluded patients who initiated any of the study medicines in the first year of data coverage in any dataset to ensure we limited the analyses to incident users. The SSA method[10] is sensitive to prescribing trends over time and adjustment was made for temporal trends using the null-effect sequence ratio as described by Tsiropolous. [19] Bootstrapped 95% confidence intervals (CI) were obtained using 500 replicates. The SSA analyses were restricted to sequences of incident dispensings within 12 months of each other to limit the effect of age and other potential time-varying covariates on the probability of exposure and outcome.
Moreover, a 12-month period has better specificity and positive predictive value compared with shorter periods. [14] Pooled estimates were obtained with a random effects model, using the generic inverse variance method. [20] 
Results
In total, 54,957 patients who received oral vancomycin and proton pump inhibitors were included in the study. Positive associations were see in all countries apart from Taiwan, where due to low use of oral vancomycin, insufficient numbers were available to determine effect ( Table 2 ). The pooled estimate showed a 2.4 fold (95% CI 1.88-3.05) increased risk 
Discussion
This multi-country study found an elevated risk of C. difficile infections after initiation of proton pump inhibitors. Our pooled estimate of 2.4 (95% CI 1.88-3.05) is slightly higher but consistent with prior research, where meta-analysis evidence reported an increased odds of 1.65 (95% CI 1.47-1.85).
[1] When our pooled analysis was limited to Korea, Japan and Taiwan, we found a three-fold increased risk which is also consistent with previous metaanalysis results from Asian countries OR 3.26, (95%CI 1.91 -5.58.).
[1] The risk was present and was of similar magnitude for each individual proton pump inhibitor.
We observed the highest risk in the Japanese data sets, with risk estimates increased three and five fold respectively in the two Japanese data sets, for which confidence intervals overlapped. These results are higher risk estimates than have been reported previously in Japan. The largest previous Japanese study, which was a multi-institution study involving 1025 cases and 878 controls that assessed hospital acquired C. difficile infections, did not find proton pump inhibitors were a risk factor for C. difficile infections, however, assessment of PPI use was limited to that prescribed during the hospital stay. [21] By comparison our results include outpatient proton pump inhibitor use up to one year prior to C. difficile infections. A small Japanese study, limited to 26 cases and 52 controls, assessed risk factors for community acquired C. difficile infections, finding no association with proton pump inhibitor use. [22] Another small study of risk of recurrent infection, involving 14 patients with recurrent infection and 62 without also did not find a significant effect of proton pump inhibitors on recurrence. [23] These latter two studies may have had insufficient sample size to demonstrate effect. Finally, a Japanese study amongst a cohort of people who had been prescribed injectable antibiotics did find proton pump inhibitors were associated with increased risk of subsequent C. difficile infections. [24] Previous research in Korea has assessed the relationship between recurrent C. difficile infections and PPIs, demonstrating an association. [25, 26] No prior studies from Korea examined the effect on incident infection.
One small study involving 84 persons from Taiwan found proton pump inhibitors were an independent risk factor for development of C. difficile infections (OR 3.2, p=0.014) [27] , while a second study found of those with C. difficile colonization, use of proton pump inhibitors was more common in those who subsequently developed infection. [28] While it has been postulated that the acid suppressions mechanism of PPIs may play a role by allowing C. difficile spores to survive the gastric environment, this may not be the mechanism as C. difficile spores can survive acid gastric contents. [29] Acid levels, though, may affect toxin expression. As we previously noted, one in-vitro study found that expression of toxin genes and their regulators were different in the presence of PPIs in some C. difficile ribotypes. [9] Another in vitro study also examining the effect of PPIs on expression of colonocyte genes found PPIs decreased their expression. [30] The consequence of decreased expression includes loss of maintenance of cell junction, and reduced production of proteins known to protect the intestinal epithelium, one of which is known to protect against C. difficile induced intestinal damage. An effect on bile acid metabolism and transport was also observed. [30] All of these effects have the potential to increase susceptibility to or worsen C. difficile infection.
Given one of the possible mechanisms by which PPIs may exert their influence on C. difficile infection is toxin expression and that toxin expression differs by ribotype, [9] our results, highlight the importance of obtaining risk estimates, where possible, from local data as data from other countries may not be directly applicable. Our results show slightly higher risk estimates in the Asian countries, however, we did not have access to clinical records and so could not ascertain any information on whether this could be related to the strain of C. difficile being treated. Another possible reason for higher risk estimates in the Asian countries, and Japan in particular, is because of inter-ethnic differences in the prevalence of CYP2C19 polymorphisms. There is a higher prevalence of the poor metaboliser phenotype of CYP2C19 in the Japanese (18-22.5%) and the Koreans (12.6%) compared to Caucasian populations (2.5-3.5%). The poor metaboliser phenotype results in raised and sustained plasma levels of PPIs, thus potentially increasing infection risk. [31] Strengths of our research include the access to national data sets for Australia, Canada, Korea, and Taiwan. Our research used a common method and a common analytic approach which ensures results are comparative with regards to method and data variables used. This is the first study of this association using a within person design, which has the advantage of inherently adjusting for measured and unmeasured confounders that are stable over time. [10] A prior study utilising SSA demonstrated that patient characteristics are often similar in the causal and non-causal groups and therefore are unlikely to affect the sequence order providing further support that the method effectively adjusts for stable confounders. [10] Given the association between C. difficile infections and PPIs has been previously described, [1, 2, 3, 4, 5] there is potential for prescribers who are aware of the association to minimise prescribing PPIs in people with C. difficile infections. However, our temporal analysis shows an increase in oral vancomycin initiation in the non-causal groups, in the weeks immediately preceding PPI initiation, suggesting this potential confounding effect was not present to any great extent in our study (Figure 2 ). In addition the sequence symmetry method only includes persons who got both medicines, thus, eliminating the bias that could occur if those with no PPI prescription after C. difficile treatment were included.
Additionally, our sensitivity analysis, using metronidazole as the outcome indicator, provides further evidence supporting the result.
Limitations of our study include lack of diagnostic information at the outpatient level in the majority of countries, and hence the reliance on oral vancomycin as the proxy indicator for C. difficile infections. Oral vancomycin, however, has been used as a marker of C. difficile infection in previous research [17] and is the sole reimbursed indication for oral vancomycin in Australia[32], Canada and Korea [33] . In Japan it is indicated for 1) "infectious enteritis (including pseudomembranous colitis)" caused by vancomycin-sensitive MRSA colitis and Clostridium difficile, and 2) "sterilization of gastrointestinal tract at bone-marrow transplantation". In the other countries it may be used for either C. difficile or staphylococcal enterocolitis. A limitation of the method was the inability to include data from Hong Kong and the inclusion of only limited data from Taiwan. In both countries the injectable formulation of vancomycin is used orally as a treatment for C. difficile infections and these dispensings could not be distinguished from vancomycin given in the injectable form for other reasons. It is possible that injectable vancomycin was also given orally in countries outside Taiwan and Hong Kong, however, we were unable to ascertain the extent of this practice. The implications of this means we may have missed some C. difficile infections, however, if this bias does exist, it is likely to have been systematic and not influenced one group more than the other. A further limitation is that oral vancomycin is second line therapy in many countries, with metronidazole being first line therapy for C. difficile infections; including in Australia, Japan and Canada. We did not use metronidazole as our primary indicator of C. difficile infections because metronidazole is also indicated for other conditions and thus may have biased the results. This limitation means that we did not include cases of C. difficile treated by metronidazole only in our primary analysis and so will not have captured all events. In addition, there are differences in the extent of capture of C. difficile infections across data sets. The Korean data set, which is a whole of country data set that includes hospital in-patient data, had the greatest number of C. difficile events. The only other data set to include hospital infections was the Japan Hamamatsu data set. All other data sets represent community treated infections. While the community treated infections may have been less serious infections, our analysis shows the risk estimates were similar across all data sets, suggesting an effect due to proton pump inhibitor use and not to differences in data capture or health systems. The variation in the data sets available limited our ability to assess differences in risk between countries. The risk of protopathic bias, where PPIs may be used in the prodromal phase of the disease, is unlikely as indigestion type symptoms are not usually associated with C. difficile infections. Further the temporal analysis shows that while the counts of persons receiving oral vancomycin is highest in the first few weeks postinitiation, the effect remains elevated over time compared to those receiving oral vancomycin prior to PPI initiation. Finally, we cannot exclude the possibility that some of the differences observed across countries may be due to differences in health care practice.
Conclusion
Our study confirms the association between PPI initiation and C. difficile infections across countries in the Asia-Pacific region. Further research to confirm reasons underpinning any risk difference in the Asian region is required. C. difficile infections are of growing concern across the world, particularly as resistance to treatments increases. [8, 34] Use of proton pump inhibitors is a modifiable risk factor for clostridium difficile infections and clinicians need to take this into consideration when treating at-risk patients.
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